Using meta-analysis of Phase II trials to predict Phase III trial results
نویسندگان
چکیده
Methods We consider a meta-analysis of nine randomised Phase II trials comparing the efficacy of two therapies for acute myocardial infarction. Results for four outcomes were collected: intracranial haemorrhage, stroke, reinfarction and total mortality. We apply univariate and multivariate random-effects meta-analysis methods, and use the obtained summary results to derive 95% prediction intervals, which give the predicted treatment effects for the four outcomes in a future trial. The multivariate approach jointly synthesizes all outcomes whilst accounting for their correlation. The methods are applicable in both frequentist and Bayesian frameworks. Predictions calculated are compared to results from subsequent Phase III trials.
منابع مشابه
Meta-analysis of randomized phase II trials to inform subsequent phase III decisions
BACKGROUND If multiple Phase II randomized trials exist then meta-analysis is favorable to increase statistical power and summarize the existing evidence about an intervention's effect in order to help inform Phase III decisions. We consider some statistical issues for meta-analysis of Phase II trials for this purpose, as motivated by a real example involving nine Phase II trials of bolus throm...
متن کاملModel‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development
The failure rate for phase III trials in oncology is high; quantitative predictive approaches are needed. We developed a model-based meta-analysis (MBMA) framework to predict progression-free survival (PFS) from overall response rates (ORR) in relapsed/refractory multiple myeloma (RRMM), using data from seven phase III trials. A Bayesian analysis was used to predict the probability of technical...
متن کاملValidation of novel imaging methodologies for use as cancer clinical trial end-points.
The success or failure of a clinical trial, of any phase, depends critically on the choice of an appropriate primary end-point. In the setting of phases II and III cancer clinical trials, imaging end-points have historically, and continue presently to play a major role in determining therapeutic efficacy. The primary goal of this paper is to discuss the validation of imaging-based markers as en...
متن کاملConditionally unbiased estimation in phase II/III clinical trials with early stopping for futility
Seamless phase II/III clinical trials combine traditional phases II and III into a single trial that is conducted in two stages, with stage 1 used to answer phase II objectives such as treatment selection and stage 2 used for the confirmatory analysis, which is a phase III objective. Although seamless phase II/III clinical trials are efficient because the confirmatory analysis includes phase II...
متن کاملApplication of Case I and Case II of Hill’s 1979 Yield Criterion to Predict FLD
Forming limit diagrams (FLDs) are calculated based on both the Marciniak and Kuczynski (M-K) model and the analysis proposed by Jones and Gillis (J-G). J-G analysis consisted of plastic deformation approximation by three deformation phases. These phases consisted of homogeneous deformation up to the maximum load (Phase I), deformation localization under constant load (phase II) and local necki...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 14 شماره
صفحات -
تاریخ انتشار 2013